A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 976-980

  Quillen, K ^a   Seldin, D C ^a   Finn, K T ^a   Sanchorawala, V ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AL amyloidosis; auto SCT; high dose melphalan; relapse

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENGRAFTMENT; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEART DISEASE; HERPES ZOSTER; HUMAN; IMMUNE STATUS; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; MALE; METABOLIC DISORDER; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; REPEAT PROCEDURE; RETREATMENT; SEPSIS; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AMYLOIDOSIS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS;

EID: 79960177953     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.239     Document Type: Article

References (17)

1. Comenzo RL. How I treat amyloidosis. Blood 2009; 114: 3147-3157.
2. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
3. Seldin DC, Anderson JJ, Sanchorawala V,Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888-1893. (Pubitemid 39202302)
4. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319-328. (Pubitemid 41098849)
5. RosenzweigM, Seldin DC, Remick DG, SkinnerM, Quillen K, Oran B, et al. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a melphalan recall reaction. Bone Marrow Transplant 2010; 45: 21-24.
6. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007; 40: 557-562. (Pubitemid 47382126)
7. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010. (Pubitemid 30412882)
8. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Brit J Haematol 2006; 135: 158-164. (Pubitemid 44401612)
9. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010; 28: 1209-1214.
10. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222-2232.
11. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-246. (Pubitemid 36416849)
12. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-2951. (Pubitemid 40446290)
13. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492-496. (Pubitemid 46105943)
14. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
15. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.
16. Hillyer CD, Comenzo RL, Miller KB, Schenkein DP, Tiegerman KO, Fogaren TA, et al. Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. Am J Hematol 1991; 36: 152-153.
17. Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int 2003; 63: 1868-1873. (Pubitemid 36513335)